MedPath

Feasibility study of the bi-weekly administration of eribulin for metastatic breast cancer

Not Applicable
Recruiting
Conditions
Metastatic breast cancer
Registration Number
JPRN-UMIN000013596
Lead Sponsor
Saitama Medical University International Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with serious complications, a history of drug hypersensitivity, brain metastases with any symptoms, active secondary cancer, or pregnant women were excluded.

Study & Design

Study Type
Interventional,observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ORR, overall response rate
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath